Freedom Investment Management’s Corcept Therapeutics CORT Stock Holding History

Freedom Investment Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9,194	Closed	-$219K	–	879
2021 Q1	$219K	Buy	+9,194	New	+$245K	0.02%	759
2020 Q4	–	Sell	-13,159	Closed	-$229K	–	623
2020 Q3	$229K	Buy	+13,159	New	+$210K	0.02%	476
2019 Q1	–	Sell	-28,358	Closed	-$379K	–	699
2018 Q4	$379K	Sell	28,358 -2,343	-8%	-$31K	0.03%	492
2018 Q3	$461K	Buy	30,701 +5,151	+20%	+$72K	0.03%	546
2018 Q2	$402K	Buy	+25,550	New	+$444K	0.02%	649

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Freedom Investment Management's CORT Position: Q2 2021 in Review

Freedom Investment Management sold out of Corcept Therapeutics (CORT) in Q2 2021, closing a stake of 9,194 shares — an estimated $219K sold.

Freedom Investment Management first reported a position in CORT in Q2 2018 and held it in 5 quarters. The position peaked at $461K in Q3 2018. 199 funds tracked by Wall St. Rank hold CORT as of Q2 2021.

Freedom Investment Management reported no remaining Corcept Therapeutics position as of Q2 2021 after selling out during the quarter.
Freedom Investment Management sold 9,194 Corcept Therapeutics shares in Q2 2021, an estimated $219K.
Freedom Investment Management first reported a position in Corcept Therapeutics in Q2 2018 and held it in 5 quarters.
Freedom Investment Management's Corcept Therapeutics position peaked at $461K in Q3 2018.
199 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2021.

Based on Freedom Investment Management's 13F filing for Q2 2021, filed 12 Aug 2021.